Proto-Oncogene Proteins c-met, antagonists & inhibitors

Name
Proto-Oncogene Proteins c-met, antagonists & inhibitors
Accession Number
DBCAT001756
Description

Not Available

Drugs
DrugDrug Description
TivantinibTivantinib has been investigated in Solid Tumors.
TepotinibAn oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations.
Drugs & Drug Targets
DrugTargetType
TivantinibHepatocyte growth factor receptortarget
TepotinibP-glycoprotein 1transporter
TepotinibCytochrome P450 3A4enzyme
TepotinibCytochrome P450 2C8enzyme
TepotinibATP-binding cassette sub-family G member 2transporter
TepotinibHepatocyte growth factor receptortarget
TepotinibNischarintarget
TepotinibMelatonin receptor type 1Btarget
TepotinibSerum albumincarrier
TepotinibAlpha-1-acid glycoprotein 1carrier
TepotinibSolute carrier family 22 member 1transporter
TepotinibSolute carrier family 22 member 2transporter
TepotinibMultidrug and toxin extrusion protein 1transporter
TepotinibMultidrug and toxin extrusion protein 2transporter
TepotinibBile salt export pumptransporter
TepotinibCytochrome P450 2C9enzyme